See Neuraxpharm’s sites

FB Health rebrands to Neuraxpharm Italy

Neuraxpharm Group makes a step forward by rebranding its subsidiary also in Italy

-PRESS RELEASE-

October 23, 2018. FB-Health, an Italian-based specialty pharmaceutical company focused on the prevention and treatment of diseases in the fields of neurology, geriatrics, psychiatry and child neuropsychiatry, has just rebranded to Neuraxpharm Italy.

Neuraxpharm Italy, located in Ascoli Piceno, has a 100% CNS-oriented portfolio of nutraceuticals and branded generics. With the rebranding in Italy, the company demonstrates its commitment to the CNS area through its new name.

The whole Group has recently rebranded to Neuraxpharm. Neuraxpharm is a leading CNS group with more than 30 years of experience and with a strong presence in the main European markets. Neuraxpharm will position itself as the specialist partner of choice in CNS with more than 100 CNS molecules offered in the European market.

Marco Marchetti, Managing Director of Neuraxpharm Italy, remarked that “we are convinced that the rebranding of our company further reinforces our leading CNS position in Italy. Our mission is to improve the quality of life for patients suffering from CNS disorders through our nutraceuticals, like Vivimind® and Seripnol®, and pharmaceutical products. The key opinion leaders in the fields of neurology, geriatrics, psychiatry and child neuropsychiatry, with whom Neuraxpharm Italy has a solid relationship, fully support the rebranding”.

In this regard, Dr. Jörg-Thomas Dierks, Chief Executive Officer of Neuraxpharm, commented that “this rebranding in Italy is of strategic importance for the whole Group, as the Italian is among the top 5 CNS markets in Europe and helps us to position ourselves as a dominant player in the CNS area as well as to be more easily identified”.

Being part of a large Group, Neuraxpharm Italy is already benefiting from a wide portfolio by adding more CNS products to the existing business in Italy and will also launch several new products in the coming years.